1. Home
  2. VGNT vs IRON Comparison

VGNT vs IRON Comparison

Compare VGNT & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versigent PLC Ordinary Shares

VGNT

Versigent PLC Ordinary Shares

N/A

Current Price

$47.14

Market Cap

3.2B

Sector

N/A

ML Signal

N/A

Logo Disc Medicine Inc.

IRON

Disc Medicine Inc.

HOLD

Current Price

$61.73

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGNT
IRON
Founded
2026
2017
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
3.1B
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
VGNT
IRON
Price
$47.14
$61.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
13
Target Price
$56.67
★ $103.17
AVG Volume (30 Days)
★ 626.7K
500.6K
Earning Date
11-04-2026
11-05-2026
Dividend Yield
★ 1.10%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 2.75
N/A
Revenue
N/A
N/A
Revenue This Year
$7.85
N/A
Revenue Next Year
$2.94
N/A
P/E Ratio
$17.22
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.44
$40.00
52 Week High
$50.25
$99.50

Technical Indicators

Market Signals
Indicator
VGNT
IRON
Relative Strength Index (RSI) 53.58 22.79
Support Level $44.87 $58.30
Resistance Level $47.35 $82.89
Average True Range (ATR) 1.63 2.46
MACD 0.02 -0.36
Stochastic Oscillator 84.14 0.68

Price Performance

Historical Comparison
VGNT
IRON

About VGNT Versigent PLC Ordinary Shares

Versigent PLC designs and manufactures low- and high-voltage electrical architectures. Its products include signal, power, and data distribution systems used in sectors such as automotive, commercial vehicles, agriculture, and energy storage. The company operates engineering and manufacturing facilities across multiple regions and serves customers through an international network.

About IRON Disc Medicine Inc.

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Share on Social Networks: